RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes.
about
Presentation of numerous viral peptides to mouse major histocompatibility complex (MHC) class I-restricted T lymphocytes is mediated by the human MHC-encoded transporter or by a hybrid mouse-human transporterAntigen processing in vivo and the elicitation of primary CTL responsesDRiPs solidify: progress in understanding endogenous MHC class I antigen processingModulation of transporter associated with antigen processing (TAP)-mediated peptide import into the endoplasmic reticulum by flavivirus infectionMHC class I antigen presentation of DRiP-derived peptides from a model antigen is not dependent on the AAA ATPase p97T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.Generating MHC class I ligands from viral gene products.Peptide antagonism as a mechanism for NK cell activation.Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase.Positional bias of MHC class I restricted T-cell epitopes in viral antigens is likely due to a bias in conservationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virusPositive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice.4-1BB ligand enhances tumor-specific immunity of poxvirus vaccinesComparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing.Presentation by a major histocompatibility complex class I molecule of nucleoprotein peptide expressed in two different genes of an influenza virus transfectantStrictly transporter of antigen presentation (TAP)-dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein.The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL).Introduction of a glycosylation site into a secreted protein provides evidence for an alternative antigen processing pathway: transport of precursors of major histocompatibility complex class I-restricted peptides from the endoplasmic reticulum to tTwo novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenLoss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapyEvidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent mannerGeneration of CD8+ T cells specific for transporter associated with antigen processing deficient cells.Amino acid substitutions in the floor of the putative antigen-binding site of H-2T22 affect recognition by a gamma delta T-cell receptor.Comparative analysis of cancer vaccine settings for the selection of an effective protocol in miceDefining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAsBoth treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses.Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes.Evidence for peptide transport across microsomal membranes.Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.The nature and extent of contributions by defective ribosome products to the HLA peptidome.Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands.Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase.Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway.The role of peptide specificity in MHC class I-restricted allogeneic responses.Alloreactivity, antigen recognition and T-cell selection: three diverse T-cell recognition problems with a common solution.The HLA likes and dislikes of allospecific and non-MHC-restricted cytotoxic T lymphocytes.Model for the in vivo assembly of nascent Ld class I molecules and for the expression of unfolded Ld molecules at the cell surface.
P2860
Q24336610-F1D6473E-0E96-402D-92B7-D6CF08F63299Q24675502-A339A26E-4B68-46D5-A068-E623B0F98A4FQ27006750-B297D894-BCA0-449A-B964-FC5B597D6B30Q27469803-A40F4776-941E-4A73-A4B4-A6744C2F5619Q28534458-74B94E13-3D6C-4A98-AB4C-B1AE51EFA308Q33519520-CB8F1A8F-22BD-431C-A222-0476847540A6Q33815388-0BB32EBF-BF0D-4221-8D6C-3077F297F736Q33933479-328D90A5-2F5B-4F45-907A-C9A8E3CE9CDAQ34130632-7CF3CA33-5E05-4E5A-B67E-AEE07A2B62FEQ34565830-D9D95174-9E26-4AF5-8A19-BF24BCFB6331Q34788858-45CCBB6D-EDBC-480D-9494-5C0FFA808F19Q34858946-8FA7A8F1-33AF-402B-82E5-149B0CDF5B74Q35580258-EEFA54E2-E7D7-4D50-93CC-E0603A8C5464Q35781892-8186AD65-DAA9-43A6-8316-0E28C5985A82Q36363817-652B2A04-4657-4EB8-B754-1DA2FC82310FQ36364290-60C528B0-EF55-406E-8B2A-9D5BC36247A1Q36365365-0CB264F9-2E05-4F3E-954C-7C197275D01AQ36367717-DA976FD3-E633-442A-A0EA-3BD9FBD578FCQ36377031-EA861FF1-292A-43F7-B2F3-738FF3E94C18Q36380570-42D8B87B-FCAB-4323-BEB8-99BC802D1B11Q36380657-C6AD064F-A508-4CCE-BC12-CD693C4EC93DQ36456190-3CE99B9F-093A-4539-9B27-8F2D9610AB0FQ36470726-75E9058E-553C-42B6-A22C-8F542BBA46CEQ36574363-325A0C20-4CA8-4FA0-A725-BB33577DDF5CQ36599550-61712DAC-C833-47CC-9157-638C7D6F824FQ36703460-2F728D2B-5B06-4A76-A898-EA29B728D098Q36859227-CDD5031D-A178-42EE-AF86-43019650E5A6Q36905953-4E973039-BD06-4740-898A-344374AE6C8CQ37208504-8651DE38-839F-4B9B-85F4-0BA236C39141Q37321654-11206172-495B-4F9E-B9B4-DD82665C4099Q37599307-66A99750-E6DF-4694-8D47-95FDF4855ABFQ37644973-1DD960C0-4FC9-4E2E-A1E6-18145B3CA626Q37725183-EA684CC8-60E3-4A39-8EB6-D3D89E03A21AQ37854496-3BD1CAF2-CD09-4E23-9B43-A7621431B938Q39359227-C31216D9-F9D0-443F-AC94-75F05BF1684AQ40381395-540480A7-6631-488A-AD58-E08310442185Q41349731-4B6D6243-F95F-4883-9A40-DF0E8BD93775Q41349742-A7EB070A-1E3B-4700-B355-C6C5099A64DDQ41349751-7E6FF299-EBCC-4E6E-8E49-C7425C4A654DQ41511463-B5DC840C-D9F6-4B0C-B0C1-15C6826652E4
P2860
RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@ast
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@en
type
label
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@ast
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@en
prefLabel
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@ast
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@en
P2093
P2860
P356
P1476
RMA/S cells present endogenous ...... icted cytotoxic T lymphocytes.
@en
P2093
P2860
P304
P356
10.1084/JEM.175.1.163
P407
P577
1992-01-01T00:00:00Z